Summary Serum levels were determined in 434 patients with benign and malignant gastrointestinal diseases and compared with the serum concentrations of carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP). The highest proportion of elevated CA-S0 levels (>17 U ml-1) was found in patients with pancreatic cancer (73%). High levels were mainly associated with advanced cancer, but also half of the patients with a resectable pancreatic tumour had an increased CA-S0 concentration. The CA-S0 level was elevated in 37-58% of patients with colorectal, gastric, hepatocellular and biliary tract cancers. In all gastrointestinal cancers, CA-50 gave additional information compared with CEA and AFP, except in hepatocellular carcinoma where AFP was the best marker.
Carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) are well established tumour markers for gastrointestinal malignancies. The serum CEA level is elevated in a large proportion of patients with gastrointestinal and in part of non-gastrointestinal cancers, but also in patients with various benign diseases (Zamcheck et al., 1972) . Therefore it is not suitable as a marker for primary diagnosis but it is valuable in the follow-up of cancer patients with an elevated CEA level prior to therapy (Cooper et al., 1979) . Alphafetoprotein is a good tumour marker in the diagnosis of hepatocellular carcinomas and yolk sack tumours. Even small localized tumours cause elevation of the marker level (Ruoslahti & Seppailii, 1979) .
A new tumour-associated antigen, CA-50, is defined by a monoclonal antibody raised against a colorectal carcinoma cell line (Lindholm et al., 1983) . The C-50 antibody reacts not only with a sialylated Lewisa-blood group substance but also with another carbohydrate structure, sialosyllactotetraose, which lacks the fucosyl residue present in the sialylated Lewisa_structure (Nilsson et al., 1985; .
The CA-50 antigen is found in serum in a high molecular weight glycoprotein fraction and on cell surfaces in gangliosides (Lindholm et al., 1983 . High serum CA-50 concentrations were originally observed in a large proportion of patients with gastrointestinal cancers, especially pancreatic cancer, and also in some non-gastrointestinal malignancies such as lung, bladder and gynaecological cancers (Holmgren et al., 1984) .
The aim of this study was to evaluate the usefulness of CA-50 in the diagnosis of gastrointestinal cancers. Serum levels of CA-50 were determined in patients with malignant and benign diseases of the colon, stomach, liver, pancreas and biliary tract and compared with the CEA and AFP concentrations.
Materials and methods

Patients
The serum levels of CA-50 were measured in 244 (Ruoslahti & Seppiilii, 1971) . The cut-off levels of 2.5ngml-1 and 25ngml-1 were used for the CEA-and AFP-measurements, respectively.
Results
Colorectal diseases
In patients with primary colorectal carcinoma, elevated (> 17 U ml-1) CA-50 values were found in 37% (Table I and  II) . The highest level was 16,000 U ml -1. Recurrence of the disease caused elevation of CA-50 in 49% of the patients (range: 2-1970 U ml -1) ( Figure 1 , Table I ). Elevated values were mainly seen in advanced diseases (Dukes' C and D), whereas only 4 out of 18 local cancers (Dukes' A and B) showed an increase of the marker concentration. A slightly elevated CA-50 value (up to 42Uml-P) was found in two out of 33 patients (6%) with benign colorectal diseases (Table I) .
Carcinoembryonic antigen was elevated (>2.5ngml-') in 67% of the patients with colorectal carcinoma (primary and recurrent) and in 21% of the patients with benign colorectal disease (Table I and II) . No correlation was found between the CA-50 and CEA concentrations (Figure 1 ). Twenty-eight percent of the cancer patients had a CA-50 level higher than any patient with benign colorectal disease. The corresponding percentage for CEA was 41%. Elevated values of both CA-50 and CEA were found in 36% of the cancer patients. The combination of elevated CA-50 and normal CEA was seen in 7% of these patients, while the percentage for the opposite combination was 35% (Figure 1 ).
Gastric diseases
The CA-50 level was elevated in 41% of the patients with gastric cancer (range: 4-1,450 U ml -1), whereas benign gastric diseases were associated with an increased concentration in 9 out of 63 patients (15%; range; 0-288 U ml-1) (Figure 2 , Table I ). Elevated CEA levels were found in 31% of the patients with gastric cancer and in 16% of the patients with benign gastric diseases (Figure 2 ; Table I ). No correlation was observed between the CA-50 and CEA levels (Figure 2 ).
Liver and biliary tract diseases
More than half of the patients with hepatic (55%) or biliary tract (58%) cancers had CA-50 levels above the cut-off value°°°o f 17 U ml-1 (Figure 3 , Table I ). Elevated CA-50 levels were also seen in almost half of the patients with benign hepatic diseases (43%) and in one third of the patients with benign biliary tract diseases (38%), especially in extrahepatic cholestasis and biliary tract infections. correlation between the CA-50 values and the serum concentrations of alkaline phosphatase or bilirubin (data not shown). AFP was elevated (>25 ng ml1) in 82% of the patients with hepatic cancer but in only 8% of the patients with biliary tract cancer (Figure 3 , Table I ). There was no correlation between the CA-50 and AFP concentrations in these patients (Figure 3 ).
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Pancreatic diseases
An increased serum CA-50 concentration was found in 73% Figure 4 Comparison of the CA-50 and CEA levels in patients with pancreatic cancer (U localized, 0 advanced) and benign pancreatic diseases (0). of the patients with pancreatic cancer (Figure 4 ; Table I ).
The highest values (up to 68,000 U ml-1) were seen in patients with advanced tumours, but also 5 out of 8 patients with a resectable pancreatic tumour had an elevated marker level (Figure 4) . Slightly or moderately elevated values (up to 145 U ml-1) were also found in 21% of the patients with benign pancreatic diseases (Figure 4 ; Table I ). Almost half of the patients with pancreatic cancer (45%) had a marker level higher than any of the patients with benign pancreatic, biliary tract or liver diseases (Figures 3 & 4) . The CEA level was elevated in 53% of the patients with pancreatic cancer and in 23% of the patients with benign pancreatic diseases (Table I) . No correlation was observed between the CA-50 and CEA concentrations in these patients (Figure 4 ).
Discussion
The highest proportion of elevated CA-50 levels was found in patients with pancreatic cancer, of which 73% had a CA-0°50 concentration higher than 17Uml-1. The CEA level was above 2.5ngml-1 in 53% of these patients, and 32% had a CEA level higher than 10ngml-1. Alpha-fetoprotein is very seldom elevated in patients with biliary tract carcinomas, whereas CA-50 detects more than half (58%) of these patients. The value of a better sensitivity of the CA-50 test is impaired by the poor specificity (62%). This is due to high marker levels found in patients with jaundice and biliary tract inflammation. However, by combining these markers the sensitivity can be increased to 73% without decreasing the specificity.
Both the CA-50 and CEA assays have a low sensitivity for gastric carcinoma, although the CA-50 assay detects 10% more carcinomas than CEA. The utility of CA-50 as a tumour marker in clinical practice still has to be evaluated. In our experience, CA-50 is valuable in the diagnosis and follow-up of patients with pancreatic cancer (Haglund et al., 1987) . In this cancer group, CA-50 seems to correlate well with CA-19.9 (Koprowski et al., 1979) , another new tumour marker related to CA-50. Experiments are in progress to study the correlation of these two tumour antigens also in other gastrointestinal cancers. The present results, however, indicate that CA-50, in combination with old tumour markers, can give additional information in patients with colorectal, gastric or biliary tract cancer.
